EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Repurposing drugs to advance the treatment of Buruli ulcer

Sanjay Singh iD, Rie Yotsu, Eric Nuremberger iD, Shashikant Srivastava iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00029-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Sanjay Singh und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA. Hauptthemen laut MEDLINE: Buruli Ulcer, Drug Repositioning, Mycobacterium ulcerans, Anti-Bacterial Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aligned with the World Health Organization’s Road Map, there is an unmet need for research to improve the treatment of Buruli ulcer caused by Mycobacterium ulcerans . The repurposing of drugs could speed up new regimen development to treat Buruli ulcer. Using a virulent reporter strain of M. ulcerans with intrinsic bioluminescence (MuAL), we compared the minimum inhibitory concentration (MIC) of moxifloxacin, bedaquiline, telacebec, tebipenem, omadacycline, and epetraborole with standard-of-care drugs—rifampin and clarithromycin. We also compared the efficacy (maximal kill or E max ) and potency (EC 50 or concentration associated with 50% of E max ) as single and two-drug combinations. The doubling time of MuAL was calculated as 3.66 (95% CI: 3.41–3.93) days. Telacebec had the lowest MIC (0.0000075 mg/L) among the eight drugs tested, followed by rifampicin (0.5 mg/L) and clarithromycin (0.5 mg/L). Epetraborole, telacebec, and moxifloxacin monotherapy at tested concentrations showed higher E max compared to clarithromycin and rifampicin. In preclinical studies, telacebec combined with rifampicin or epetraborole and epetraborole combinations with moxifloxacin and omadacycline were superior to the rifampin-clarithromycin combination. The MuAL strain is useful in the rapid screening of drugs’ efficacy and potency against M. ulcerans . We should leverage the progress made in the tuberculosis drug development pipeline to repurpose the drugs for the rapid development of new therapeutic modalities for Buruli ulcer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Buruli UlcerDrug RepositioningMycobacterium ulceransAnti-Bacterial AgentsMicrobial Sensitivity TestsClarithromycinRifampinMoxifloxacinHumansDiarylquinolinesTetracyclinesAnimals

Stichwörter der Autor:innen

Buruli ulcerMycobacterium ulceransautoluminescencedrug susceptibilityrepurposing

Substanzen

Anti-Bacterial AgentsClarithromycinRifampinMoxifloxacinDiarylquinolinesbedaquilineomadacyclineTetracyclines

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA.
  • Department of Tropical Medicine and Infectious Disease, School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana, USA.
  • Center for Tuberculosis Research, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Cellular and Molecular Biology, Center for Biomedical Research, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA.

ORCID-Profile: Sanjay Singh, Eric Nuremberger, Shashikant Srivastava

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)

Zitieren

APA

Singh, S., Yotsu, R., Nuremberger, E., & Srivastava, S. (2025). Repurposing drugs to advance the treatment of Buruli ulcer. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00029-25

Vancouver

Singh S, Yotsu R, Nuremberger E, Srivastava S. Repurposing drugs to advance the treatment of Buruli ulcer. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00029-25

BibTeX
@article{Singh2025,
  author = {Singh, Sanjay and Yotsu, Rie and Nuremberger, Eric and Srivastava, Shashikant},
  title = {Repurposing drugs to advance the treatment of Buruli ulcer},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00029-25}
}
Kostenlos starten →